Stronger treatment after surgery for high-risk glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a more intense chemotherapy plan for people with glioblastoma who had only partial removal of their tumor or whose tumor grew back quickly. The goal is to see if this approach can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with glioblastoma, a type of brain cancer.
- Your tumor was only partly removed during surgery, or it started growing again within 4 to 6 weeks after surgery.
- You are at least 18 years old.
- Your blood counts, liver, kidneys, and heart function are good enough to handle the treatment.
- You have not had radiation therapy to the brain before.
- You are not pregnant or breastfeeding and agree to use birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stronger combination of treatments given after surgery for people with glioblastoma (GBM) that was only partially removed or that starts growing again quickly. It aims to see if this approach can help control the tumor better. You may be eligible if you are newly diagnosed, over 18, have good organ function, and do not have other serious health issues.
This trial tests a combination of two drugs—sintilimab (an immunotherapy that helps your immune system fight cancer) and low-dose bevacizumab (which blocks blood vessel growth to tumors)—for people whose glioblastoma has returned after standard treatment. The goal is to see if this combo can slow or stop the cancer with fewer side effects.
This Phase 2 trial tests an individualized treatment approach for glioblastoma or gliosarcoma based on your tumor’s lab tests. It may help by matching therapy to tumor features and by checking how well this strategy works after surgery and planned radiation.
This trial tests combining an immunotherapy drug (adebrelimab) with the standard chemotherapy temozolomide, with or without hyperbaric oxygen treatment, for patients with newly diagnosed glioblastoma who have already completed standard radiation and chemotherapy. The goal is to see if this combination can improve outcomes.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This trial tests a shorter, more intense course of radiation therapy (hypofractionated radiotherapy) for people with newly diagnosed glioblastoma who have had surgery. The goal is to see if this approach is safe and works well for treating the tumor.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.